SCHEMBL8094908

SCHEMBL8094908

NC(=O)c1ccc(-c2cc(-c3ccc(C(F)(F)F)cc3)on2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.47
CYP2C19 P33261 1/20 0.47
ACR P10323 1/20 0.47
MAOB P27338 2/20 0.47
MAOA P21397 1/20 0.47
TRPV1 Q8NER1 1/20 0.47
MAP2K4 P45985 1/20 0.47
CASP1 P29466 1/20 0.47
P2RY14 Q15391 6/20 0.47
OPRD1 P41143 2/20 0.47
KCNH2 Q12809 1/20 0.47
PTGS2 P35354 2/20 0.45
SIGMAR1 Q99720 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
POLB P06746 1/20 0.44
MAPT P10636 1/20 0.44
MAPK1 P28482 1/20 0.44
DHODH Q02127 1/20 0.43
FAAH O00519 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8175170 1.00 CYP3A4 (0.47) CYP3A4CYP2C19ACRMAOBMAOA
SCHEMBL8183194 0.88 ABCB1 (0.55) CYP3A4CYP2C19MAOBMAOATRPV1
SCHEMBL5202132 0.88 ABCB1 (0.55) CYP3A4CYP2C19MAOBMAOATRPV1
SCHEMBL8108067 0.84 HDAC4 (0.54) CYP3A4CYP2C19ACRMAOBMAOA
SCHEMBL5209139 0.84 MAPT (0.51) CYP3A4CYP2C19MAOBMAOATRPV1
SCHEMBL8167904 0.84 MAPT (0.51) CYP3A4CYP2C19MAOBMAOATRPV1
SCHEMBL31341155 0.83 CYP3A4 (0.50) CYP3A4CYP2C19ACRMAOBMAOA
SCHEMBL8094911 0.83 NPC1 (0.67) CYP2C19PTGS2NPC1RAB9AMAPT
SCHEMBL8091726 0.83 PTPN1 (0.56) PTGS2NPC1RAB9APOLBMAPT
SCHEMBL18031147 0.81 HSD17B1 (0.59) CYP3A4CYP2C19MAOBMAOATRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3311813-A1 THERAPEUTIC ISOXAZOLE COMPOUNDS Dart Neuroscience (Cayman) Ltd (KY) 2018-04-25 EP disclosed
US-20170204111-A1 THERAPEUTIC ISOXAZOLE COMPOUNDS DART NEUROSCIENCE LLC 2017-07-20 US disclosed
US-9650349-B2 Therapeutic isoxazole compounds DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2017-05-16 US disclosed
US-20150336941-A1 THERAPEUTIC ISOXAZOLE COMPOUNDS DART NEUROSCIENCE LLC 2015-11-26 US disclosed
US-9029397-B2 Therapeutic isoxazole compounds DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2015-05-12 US disclosed
US-8921399-B2 Therapeutic isoxazole compounds DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2014-12-30 US disclosed
WO-2009029632-A1 THERAPEUTIC ISOXAZOLE COMPOUNDS HELICON THERAPEUTICS, INC. (US) 2009-03-05 WO disclosed
WO-2000045799-A2 USE OF SUBSTITUTED ISOXAZOL CARBOXYLIC ACIDS AND DERIVATIVES AND NOVEL SUBSTANCES BAYER AKTIENGESELLSCHAFT (DE) 2000-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150336941-A1 THERAPEUTIC ISOXAZOLE COMPOUNDS MAOB, MAOA, XDH CYP3A4 182/4885CYP2C19 24/4885ACR 4570/4885
US-20170204111-A1 THERAPEUTIC ISOXAZOLE COMPOUNDS MAOB, MAOA, XDH CYP3A4 182/4885CYP2C19 24/4885ACR 4570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.